It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Preclinical studies have revealed that the elevation of nicotinamide adenine dinucleotide (NAD + ) upon the administration of nicotinamide mononucleotide (NMN), an NAD + precursor, can mitigate aging-related disorders; however, human data on this are limited. We investigated whether the chronic oral supplementation of NMN can elevate blood NAD + levels and alter physiological dysfunctions in healthy older participants. We administered 250 mg NMN per day to aged men for 6 or 12 weeks in a placebo-controlled, randomized, double-blind, parallel-group trial. Chronic NMN supplementation was well tolerated and caused no significant deleterious effect. Metabolomic analysis of whole blood samples demonstrated that oral NMN supplementation significantly increased the NAD + and NAD + metabolite concentrations. There were nominally significant improvements in gait speed and performance in the left grip test, which should be validated in larger studies; however, NMN exerted no significant effect on body composition. Therefore, chronic oral NMN supplementation can be an efficient NAD + booster for preventing aging-related muscle dysfunctions in humans.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 The University of Tokyo, Department of Diabetes & Metabolic Diseases, Graduate School of Medicine, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
2 The University of Tokyo Hospital, Data Science Office, Clinical Research Promotion Center, Tokyo, Japan (GRID:grid.412708.8) (ISNI:0000 0004 1764 7572)
3 University of Toyama, Department of Molecular and Medical Pharmacology, Faculty of Medicine, Toyama, Japan (GRID:grid.267346.2) (ISNI:0000 0001 2171 836X)
4 The University of Tokyo Hospital, The University of Tokyo, Department of Clinical Nutrition Therapy, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
5 Mitsubishi Corporation Life Sciences Limited, Tokyo, Japan (GRID:grid.465204.1) (ISNI:0000 0001 2284 8174)
6 Department of Radiology, Tokyo Metropolitan Police Hospital Tokyo, Tokyo, Japan (GRID:grid.417117.5) (ISNI:0000 0004 1772 2755)
7 The University of Tokyo Hospital, Department of Radiation Technology, Tokyo, Japan (GRID:grid.412708.8) (ISNI:0000 0004 1764 7572)
8 The University of Tokyo, Department of Diabetes & Metabolic Diseases, Graduate School of Medicine, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X); The University of Tokyo Hospital, The University of Tokyo, Department of Clinical Nutrition Therapy, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
9 Toranomon Hospital, Tokyo, Japan (GRID:grid.410813.f) (ISNI:0000 0004 1764 6940)